Real-time PCR quantification of major Wilms tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

Leukemia

Volumn 26, Issue 9, 2012, Pages 2086-2095

  Kramarzova, K ^a   Stuchly, J ^a   Willasch, A ^b   Gruhn, B ^c   Schwarz, J ^d   Cermak, J ^d   MacHova Polakova, K ^d   Fuchs, O ^d   Stary, J ^a   Trka, J ^a   Boublikova, L ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b GOETHE UNIVERSITY   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

acute myeloid leukemia; isoforms; myelodysplastic syndrome; real time quantitative PCR (qPCR); Wilms' tumor gene 1 (WT1)

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW; CHILD; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; WT1 PROTEINS; YOUNG ADULT;

EID: 84865866410     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.76     Document Type: Article

References (55)

1. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177-187. (Pubitemid 33758858)
2. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
3. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141-161. (Pubitemid 32786908)
4. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897-1909. (Pubitemid 32397392)
5. Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003; 116(Pt 9): 1653-1658. (Pubitemid 36582152)
6. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1-17. (Pubitemid 46965072)
7. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876. (Pubitemid 46672061)
8. Burwell EA, McCarty GP, Simpson LA, Thompson KA, Loeb DM. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene 2007; 26: 3423-3430. (Pubitemid 46788886)
9. Scholz H, Kirschner KM. Oxygen-dependent gene expression in development and cancer: lessons learned from the Wilms' tumor gene, WT1. Front Mol Neurosci 4: 4.
10. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991; 88: 9618-9622. (Pubitemid 21915682)
11. Hewitt SM, Hamada S, McDonnell TJ, Rauscher 3rd FJ, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995; 55: 5386-5389.
12. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher 3rd FJ. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993; 268: 21271-21275. (Pubitemid 23292317)
13. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 1996; 271: 8646-8654. (Pubitemid 26123279)
14. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet 2004; 13: 405-415. (Pubitemid 38239792)
15. Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem 2006; 281: 28122-28130. (Pubitemid 44414526)
16. Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 2004; 13: 463-471. (Pubitemid 38239797)
17. Florio F, Cesaro E, Montano G, Izzo P, Miles C, Costanzo P. Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms. Hum Mol Genet 19: 3544-3556.
18. Dutton JR, Lahiri D, Ward A. Different isoforms of the Wilms' tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus. Cell Prolif 2006; 39: 519-535. (Pubitemid 44760203)
19. Wang ZY, Qiu QQ, Huang J, Gurrieri M, Deuel TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 1995; 10: 415-422.
20. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T et al. Antiapoptotic function of 17AA( +)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-4229. (Pubitemid 44079455)
21. Bickmore WA, Oghene K, Little MH, Seawright A, van Heyningen V, Hastie ND. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. Science 1992; 257: 235-237.
22. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998; 12: 3217-3225. (Pubitemid 28496266)
23. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003. (Pubitemid 29335852)
24. Dechsukhum C, Ware JL, Ferreira-Gonzalez A, Wilkinson DS, Garrett CT. Detection of a novel truncated WT1 transcript in human neoplasia. Mol Diagn 2000; 5: 117-128.
25. Dumur CI, Dechsukhum C, Wilkinson DS, Garrett CT, Ware JL, Ferreira-Gonzalez A. Analytical validation of a real-time reverse transcription-polymerase chain reaction quantitation of different transcripts of the Wilms' tumor suppressor gene (WT1). Anal Biochem 2002; 309: 127-136.
26. Renshaw J, King-Underwood L, Pritchard-Jones K. Differential splicing of exon 5 of the Wilms tumour (WTI) gene. Genes Chromosomes Cancer 1997; 19: 256-266. (Pubitemid 27330237)
27. Moorwood K, Salpekar A, Ivins SM, Hall J, Powlesland RM, Brown KW et al. Transactivation of the WT1 antisense promoter is unique to the WT1[f+r] isoform. FEBS Lett 1999; 456: 131-136. (Pubitemid 29339055)
28. Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, Kuttenn F et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997; 17: 467-470. (Pubitemid 27518399)
29. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437-447. (Pubitemid 121001458)
30. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006; 15(special issueno 2): R196-R201. (Pubitemid 44446794)
31. Yang C, Romaniuk PJ. The ratio of +-KTS splice variants of the Wilms' tumour suppressor protein WT1 mRNA is determined by an intronic enhancer. Biochem Cell Biol 2008; 86: 312-321.
32. Gu W, Hu S, Chen Z, Qiu G, Cen J, He B et al. High expression of WT1 gene in acute myeloid leukemias with more predominant WT1 +17AA isoforms at relapse. Leuk Res 2010; 34: 46-49.
33. Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004; 83: 745-750. (Pubitemid 39485544)
34. Ishikawa Y, Kiyoi H, Naoe T. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Leuk Res May 35: 685-688.
35. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A et al. Wilms' tumor gene WT1 17AA(r)/KTS(f) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006; 97: 259-270.
36. Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, Hammarskjold ML. The Wilms' tumor 1 (WT1) gene ( +KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron. Genes Dev 2006; 20: 1597-1608. (Pubitemid 43901099)
37. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S et al. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 2008; 32: 701-711. (Pubitemid 351330477)
38. Moriya S, Takiguchi M, Seki N. Expression of the WT1 gene-KTS domain isoforms suppresses the invasive ability of human lung squamous cell carcinoma cells. Int J Oncol 2008; 32: 349-356. (Pubitemid 351188301)
39. Morrison AA, Venables JP, Dellaire G, Ladomery MR. The Wilms tumour suppressor protein WT1 ( +KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. Biochem Cell Biol 2006; 84: 789-798. (Pubitemid 46121604)
40. Han Y, San-Marina S, Yang L, Khoury H, Minden MD. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells. Breast Cancer Res 2007; 9: R43.
41. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254-263. (Pubitemid 43148663)
42. Krug U, Yasmeen A, Beger C, Baumer N, Dugas M, Berdel WE et al. Cyclin A1 regulates WT1 expression in acute myeloid leukemia cells. Int J Oncol 2009; 34: 129-136.
43. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357. (Pubitemid 38072573)
44. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003; 17: 2474-2486. (Pubitemid 38072587)
45. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009; 23: 1472-1479.
46. Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M, Trka J et al. WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase. Leuk Res 2008; 32: 1393-1399.
47. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P et al. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313-318. (Pubitemid 32762229)
48. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121. (Pubitemid 35203456)
49. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004; 112: 79-84. (Pubitemid 38716252)
50. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381-1389.
51. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 2004; 125: 590-600. (Pubitemid 38747961)
52. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416-1423. (Pubitemid 41148947)
53. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507-1515. (Pubitemid 46638771)
54. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-933. (Pubitemid 39049900)
55. Rodrigues PC, Oliveira SN, Viana MB, Matsuda EI, Nowill AE, Brandalise SR et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2007; 49: 133-138. (Pubitemid 47041101)